Material Agreements (Details) $ in Thousands									2 Months Ended	12 Months Ended		17 Months Ended	26 Months Ended	38 Months Ended
	Oct. 23, 2023 USD ($)	Mar. 27, 2023 USD ($)	Mar. 02, 2023 USD ($)	Oct. 26, 2022 USD ($)	Sep. 26, 2022 USD ($)	May 17, 2022 USD ($) d installment	Nov. 03, 2020 USD ($)	Apr. 01, 2016 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 20, 2019 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										$ 50,583	$ 47,680
Pro rata portion of target bonus						$ 280
Cash payment representing 90 days of base pay						$ 150
Days of base pay | d						90
Severance costs						$ 263
Number of installments | installment						3
Severance period (in months)						18 months
Coverage duration						18 months
Consulting fee						$ 10
Assertio Holdings, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from collaborators				$ 9,000
Contingent consideration, milestone payments				$ 6,000
First Seven Months
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs						53
Eighth Month
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs						70
Ninth through Eighteenth Month
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs						$ 88
License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										$ 5,376	$ 2,351
Commercial Exploitation Agreement with Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement term										7 years
Automatic renewal period of agreement			1 year							1 year
Revenues										$ 5,482
Royalty obligations, net			$ 11,482
Supplemental Agreement with Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues												$ 40,750
License Agreement with Sunovion Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 22,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	17,000
License Agreement with Sunovion Pharmaceuticals, Inc Milestones | License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues								$ 4
License Agreement with Sunovion Pharmaceuticals, Inc. Upfront
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 5,000
Marathon Pangolin Royalty LLC | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenues, net							$ 125,000
Marathon Pangolin Royalty LLC | Monetization Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenues, net							40,000		$ 10,000				$ 50,000	$ 50,000
Proceeds from debt, contingent on additional milestones							$ 75,000
Atnahs Pharma UK Limited | License & Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenues, net					$ 3,500
Agreement to Terminate CLA with KemPharm | License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										$ 1,500
Haisco Pharmaceutical Group Co., Ltd, Upfront Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, receivable, after allowance for credit loss															$ 7,000
Atnahs Pharma UK Limited, Amended Agreement | License & Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenues, net		$ 2,000